期刊文献+

T淋巴细胞亚群和DNA倍体检测在腹水鉴别诊断中的价值 被引量:4

Value of T lymphocyte subset determination and DNA ploidy analysis for differential diagnosis of ascites
下载PDF
导出
摘要 目的:探讨T淋巴细胞亚群和DNA倍体检测在腹水鉴别诊断中的价值.方法:腹水患者74例,其中结核性腹膜炎24例,肝硬化21例,癌性腹水29例,流式细胞仪测定腹水T淋巴细胞亚群和DNA倍体.结果:腹水中T淋巴细胞(CD3^+)、T辅助/诱导细胞亚群(CD4^+)、T辅助细胞亚群/T抑制细胞亚群(CD4^+/CD8^+)所占比例从大到小依次为结核性腹膜炎(CD3^+:86.2%±5.1%,CD4^+:64_3%±6.4%,CD4^+/CD8^+:3.20%±0.30%)、癌性腹水(65.7%±4.6%,32.5%±2.2%,1.04%±0.11%)、肝硬化腹水(15.1%±2.7%,3.6%±0.5%,0.36%±0.05%)(三组间P<0.01),CD8^+比例从小到大依次为肝硬化腹水(10.1%±3.2%)、结核性腹膜炎(20.1%±4.3%)、癌性腹水(31.3%±5.2%)(三组间P<0.01).腹水DNA倍体阳性率癌性腹水达89.7%(26/29),与结核性腹膜炎4.2%(1/24)和肝硬化4.7%(1/21)具有显著性差异(P<0.01).结论:T淋巴细胞亚群和DNA倍体在结核性腹膜炎、肝硬化及癌性腹水存在显著差异,其检测可用于腹水的鉴别诊断. AIM: To investigate the value of T lymphocyte subset determination and DNA ploidy analysis for differential diagnosis of ascites. METHODS: In 74 cases of ascites, 24 with tuberculous peritonitis, 21 with liver cirrhosis and 29 with carcinomatous ascites, T lymphocyte subsets and DNA ploidy in ascitic fluid were detected by flow cytometry. RESULTS: In descending order of T lymphocyte (CD3^+), helper/inducer T lymphocyte (CD4^+), and helper T lymphocyte/suppressor T lymphocyte (CD4^+/CD8^+) in ascitic fluid, tuberculous peritonitis (CD3^+: 86.2% + 5.1%, CD4~: 64.3% ± 6.4%, CD4^+/CD8^+: 3.20% ± 0.30%), carcinoma- tous ascites (65.7% ± 4.6%, 32.5% ± 2.2%, 1.04 %± 0.11%) and liver cirrhosis (15.1% ±2.7%, 3.6%± 0.5%, 0.36% ± 0.05%) (P 〈 0.01) were determined. In ascending order, CD8^+, liver cirrhosis (10.1% ± 3.2%), tuberculous peritonitis (20.1% ± 4.3%) and carcinomatous ascites (31.3% ± 5.2%) (P 〈 0.01) were determined. The positive rate from DNA ploidy analysis in carcinomatous ascites (89.7%, 26/29) was significantly higher than that in tuberculous peritonitis (4.2%, 1/21) or liver cirrhosis (4.7%, 1/27) (P 〈 0.01). CONCLUSION: T lymphocyte subsets and DNA ploidy in ascitic fluid show obvious differences among patients with tuberculous peritonitis, liver cirrhosis and carcinomatous ascites. T lym- phocyte subset determination and DNA ploidy analysis are thus useful for the differential diagnosis of ascites.
出处 《世界华人消化杂志》 CAS 北大核心 2007年第17期1972-1975,共4页 World Chinese Journal of Digestology
关键词 T淋巴细胞亚群 DNA倍体 腹水 流式细胞 鉴别诊断 T lymphocyte subsets DNA ploidy Ascites Flow cytometry Differential diagnosis
  • 相关文献

参考文献2

二级参考文献26

  • 1Zhao-You Tang Liver Cancer Institute & Zhongshan Hospital of Fudan University Professor of Surgery Chairman.Liver Cancer Institute of Fudan University(previous Liver Cancer Institute of Shanghai Medical University)136 Yixueyuan Road,Zhongshan Hospital,Shanghai 200032,China..Hepatocellular Carcinoma-Cause,Treatment and Metastasis[J].World Journal of Gastroenterology,2001,7(4):445-454. 被引量:214
  • 2[1]Rowinsky EK,Donehower RC.Paclitaxel (taxol) N Engl J Med 1995; 332:1004-1014
  • 3[2]Chang YF,Li LL,Wu CW,Liu TY,Lui WY,P'eng FK,Chi CW.Paclitaxel-induced apoptosis in human gastric carcinoma cell lines.Cancer 1996; 77:14-18
  • 4[3]Kim YH,Shin SW,Kim BS,Kim JH,Kim JG,Mok YJ,Kim CS,Rhyu HS,Hyun JH,Kim JS.Paclitaxel,5-fluorouracil,and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.Cancer 1999; 85:295-301
  • 5[4]Murad AM,Petroianu A,Guimaraes RC,Aragao BC,Cabral LO,Scalabrini-Neto AO.Phase Ⅱ trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer:a novel,safe,and effective regimen.Am J Clin Oncol 1999; 22:580-586
  • 6[5]Lokich JJ,Sonneborn H,Anderson NR,Bern MM,Coco FV,Dow E,Oliynyk P.Combined paclitaxel,cisplatin,and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.Cancer 1999; 85:2347-2351
  • 7[6]Kollmannsberger C,Quietzsch D,Haag C,Lingenfelser T,Schroeder M,Hartmann JT,Baronius W,Hempel V,Clemens M,Kanz L,Bokemeyer C.A phase Ⅱ study of paclitaxel,weekly,24-hour continous infusion 5-fluorouracil,folinic acid and cisplatin in patients with advanced gastric cancer.Br J Cancer 2000; 83:458-462
  • 8[7]Garcia AA,Leichman CG,Lenz HJ,Baranda J,Lujan R,Casagrande Y,Leichman L.Phase Ⅱ trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic,measurable adenocarcinoma of the stomach.Jpn J Clin Oncol 2001; 31:275-278
  • 9[8]Yamada Y,Shirao K,Ohtsu A,Boku N,Hyodo I,Saitoh H,Miyata Y,Taguchi T.Phase Ⅱ trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.Ann Oncol 2001; 12:1133-1137
  • 10[9]Wiernik PH,Schwartz EL,Einzig A,Strauman JJ,Lipton RB,Dutcher JP.Phase Ⅰ trial of taxol given as a 24-hour infusion every 21 days:responses observed in metastatic melanoma.J Clin Oncol 1987; 5:1232-1239

共引文献24

同被引文献60

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部